Hedera Dx, the European techbio company headquartered in Switzerland, just announced the closing of a €15 million Series A financing round to drive advanced cancer care. The funding will fuel Hedera Dx's mission to overcome structural barriers that prevent cancer patients from accessing targeted cancer therapies. .

总部位于瑞士的欧洲技术生物公司Hedera Dx刚刚宣布完成了一轮1500万欧元的A轮融资，以推动先进的癌症治疗。这笔资金将推动Hedera Dx克服阻止癌症患者获得靶向癌症治疗的结构性障碍的使命。

Outside the U.S., where centralized testing dominates, healthcare systems require diagnostics to be performed within hospital labs. Founded in 2021,

在美国以外，集中式检测占主导地位，医疗系统要求诊断在医院实验室进行。成立于2021年，

Hedera Dx

货币Dx

has developed blood-based cancer testing solutions, known as liquid biopsies, to allow for cost efficient and easy to adopt in-house testing of cancers patients. The solution combines affordability with unprecedented quality and is already deployed across 11 European countries. The founders have led and scaled some of the most relevant European genetics companies and operations (including Blueprint Genetics, Roche and Molecular Health) and are now focused on building the next global leader in healthcare..

开发了基于血液的癌症检测解决方案，即液体活检，以实现成本效益高且易于采用的院内癌症患者检测。该解决方案将经济实惠与前所未有的高质量相结合，已部署在11个欧洲国家。创始人曾领导并扩展了一些最具影响力的欧洲基因公司和业务（包括Blueprint Genetics、罗氏和Molecular Health），现在专注于打造医疗保健领域的下一个全球领导者。

The company based at Biopôle Lausanne is now quickly becoming Europe’s leading platform for precision oncology. In addition to advanced molecular profiling of cancer patients that provides physicians with insights for treatment decisions, the AI-native platform also uncovers patient-centric insights from real-world data to support the development of next generation oncology treatments..

总部位于洛桑生物园的这家公司现正迅速成为欧洲领先的精准肿瘤学平台。除了提供癌症患者的高级分子分析，为医生提供治疗决策依据外，这个原生人工智能平台还从真实世界数据中挖掘以患者为中心的见解，以支持下一代肿瘤治疗的开发。

The €15 million Series A funding round was led by

1500万欧元的A轮融资由

Vsquared Ventures

V平方创投

, with

，具有

Tesi

论文

also joining as a new investor alongside significant participation from existing backers

同时加入的新投资者，现有支持者也积极参与其中

Helsana HealthInvest

赫尔斯安娜健康投资

,

，

Eyrir Venture Management

艾尔风险投资管理

,

，

Inventure

发明冒险

and

和

Top Harvest

丰收

. The funding is set bring modern cancer care to patients across the globe.

这笔资金将用于为全球患者带来现代化的癌症治疗。

'At Hedera, we are building the infrastructure to make precision cancer care accessible to every patient and clinician — globally,' said Tommi Lehtonen, CEO and co-founder of Hedera Dx. 'While there is a large number of personalized cancer treatments on the market, a very large part of patients still can't access them.

“在Hedera，我们正在构建基础设施，以使精准癌症护理能够惠及全球每一位患者和临床医生，”Hedera Dx首席执行官兼联合创始人Tommi Lehtonen表示。“尽管市场上有许多个性化的癌症治疗方法，但仍有很大一部分患者无法获得这些治疗。”

Our solutions empower hospital labs to perform sophisticated molecular diagnostics locally and cost efficiently.'.

我们的解决方案使医院实验室能够本地化且经济高效地进行复杂的分子诊断。

Dr. Lise Rechsteiner, General Partner at Vsquared Ventures, said: 'Hedera Dx is addressing a critical gap in global oncology care. Hedera's approach tackles the specific challenges of hospital in-house testing and results in more patients getting tested and more patients having access to targeted therapies.

Vsquared Ventures的普通合伙人莉丝·雷施泰纳博士说：“Hedera Dx正在填补全球肿瘤学护理中的一个关键空白。Hedera的方法解决了医院内部测试的具体挑战，使更多患者得到检测，并让更多患者获得靶向治疗。”

Hedera Dx’s combination of diagnostics and powerful real-world data capabilities positions them to become the definitive leader in precision oncology within healthcare systems outside the US.”.

Hedera Dx结合了诊断和强大的真实世界数据能力，这使得他们有望成为美国以外医疗系统中精准肿瘤学的绝对领导者。

“We’re not only improving access to advanced cancer care for patients — we are creating an entirely new platform for real-world insights, driving access to life-saving precision oncology treatments and fueling the next wave of innovative cancer therapies” said Dr. Christian Meisel, CMO and co-founder of Hedera Dx.The Series A funding will support continued commercial expansion and further development of the company's real-world data infrastructure, addressing the vast global oncology market..

“我们不仅在改善患者获得先进癌症治疗的机会，还在创建一个全新的真实世界洞察平台，推动获得挽救生命的精准肿瘤治疗，并助力下一波创新癌症疗法的发展。” Hedera Dx的首席医疗官兼联合创始人克里斯蒂安·梅塞尔博士表示。本轮融资将支持公司持续的商业扩展，并进一步开发其真实世界数据基础设施，以应对全球庞大的肿瘤市场。

(PR)

（波多黎各）

0

0

Comments

评论

Back to all news

返回所有新闻

Please

请

login

登录

or

或

sign up

注册

to comment.

评论。

Commenting guidelines

评论指南

Send

发送